Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial.
Journal: The Lancet. Neurology
Published: November 06, 2025
Levodopa differentially modulates spectral features in cerebellum and basal ganglia in a rodent model of Parkinson's disease.
Journal: Experimental neurology
Published: May 02, 2025
Anti-IgLON-5 disease presenting with axial dystonia and acetazolamide-responsive apnea.
Journal: Clinical neurology and neurosurgery
Published: April 06, 2025
Long-Term Safety and Efficacy of Repeated Cycles of RimabotulinumtoxinB in the Treatment of Chronic Sialorrhea: Results of the OPTIMYST Trial.
Journal: Neurology and therapy
Published: February 07, 2025
Corrigendum to "Assessing the location, relative expression and subclass of dopamine receptors in the cerebellum of hemi-parkinsonian rats" [Neuroscience 521 (2023) 1-19].
Journal: Neuroscience
Published: November 03, 2024
Investigation of non-invasive focused ultrasound efficacy on depressive-like behavior in hemiparkinsonian rats.
Journal: Experimental brain research
Published: September 30, 2023
Time to initiation of symptomatic treatment in untreated Parkinson disease in the Parkinson progression marker initiative cohort: A 10-year follow up.
Journal: Parkinsonism & related disorders
Published: February 26, 2023
Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial.
Journal: Annals of internal medicine
Published: November 07, 2022
Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study.
Journal: Clinical parkinsonism & related disorders
Published: February 08, 2022
Narcolepsy genetic marker HLA DQB1*06:02 and excessive daytime sleepiness in Parkinson disease patients treated with dopaminergic agents.
Journal: Journal of neurology
Published: July 30, 2021
Last Updated: 09/26/2026